FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136244088> ?p ?o ?g. }

• W3136244088 abstract "The treatment of anaplastic lymphoma kinase (ALK)-positive locally advanced non-small-cell lung cancer (NSCLC) is challenging because there is no randomized controlled trial has been reported. The value of neoadjuvant and adjuvant targeted therapy remains unclear. Herein, we show that systemic treatment with ALK inhibitor crizotinib before surgery can provide the potential to cure the initially inoperable tumor. A 27-year-old man was diagnosed with a stage IIIAcT3N2M0 (7 th UICC/AJCC) upper left lung adenocarcinoma harboring EML4-ALK fusion gene. Clinically, the patient had a large primary lesion adjacent to the pericardium and regional lymph node metastasis at the ipsilateral mediastinum. Poor tumor response was observed after 3 cycles of chemotherapy (gemcitabine plus cisplatin), and upon multidisciplinary discussion, the patient was started with 250 mg crizotinib twice daily. Successive clinical examinations showed a progressive reduction of the lesions. After 2 months of therapy, the patient was downstaged to cT2aN2M0, then video-assisted thoracic surgery was performed and the final histopathological stage was ypT2aN2M0. The treatment with crizotinib (250 mg, qd) was continued more than 30 months post surgery and stopped until intracranial oligometastasis. The patient’s overall survival (OS) time is 68 months at last follow-up. This case presented here supports the use of neoadjuvant and adjuvant treatment with ALK inhibitors in ALK positive locally advanced NSCLC." @default.
• W3136244088 created "2021-03-29" @default.
• W3136244088 creator A5006422020 @default.
• W3136244088 creator A5014341292 @default.
• W3136244088 creator A5018021256 @default.
• W3136244088 creator A5025216680 @default.
• W3136244088 creator A5033704922 @default.
• W3136244088 creator A5048339590 @default.
• W3136244088 creator A5081538316 @default.
• W3136244088 creator A5085965802 @default.
• W3136244088 date "2021-03-17" @default.
• W3136244088 modified "2023-10-17" @default.
• W3136244088 title "Case Report: Neoadjuvant and Adjuvant Crizotinib Targeted Therapy in Stage IIIA-N2 ALK-Positive Non-Small-Cell Lung Cancer" @default.
• W3136244088 cites W1983276333 @default.
• W3136244088 cites W2004797311 @default.
• W3136244088 cites W2019715861 @default.
• W3136244088 cites W2026236562 @default.
• W3136244088 cites W2048560132 @default.
• W3136244088 cites W2096065464 @default.
• W3136244088 cites W2096156234 @default.
• W3136244088 cites W2098536748 @default.
• W3136244088 cites W2099530756 @default.
• W3136244088 cites W2110590052 @default.
• W3136244088 cites W2111662961 @default.
• W3136244088 cites W2118726443 @default.
• W3136244088 cites W2150424194 @default.
• W3136244088 cites W2160982674 @default.
• W3136244088 cites W2228221433 @default.
• W3136244088 cites W2746310128 @default.
• W3136244088 cites W2768989095 @default.
• W3136244088 cites W2770828094 @default.
• W3136244088 cites W2785110924 @default.
• W3136244088 cites W2791498761 @default.
• W3136244088 cites W2887380463 @default.
• W3136244088 cites W2888297236 @default.
• W3136244088 cites W2889646458 @default.
• W3136244088 cites W2899724008 @default.
• W3136244088 cites W2951872058 @default.
• W3136244088 cites W2982221186 @default.
• W3136244088 doi "https://doi.org/10.3389/fonc.2021.655856" @default.
• W3136244088 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8010235" @default.
• W3136244088 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33816312" @default.
• W3136244088 hasPublicationYear "2021" @default.
• W3136244088 type Work @default.
• W3136244088 sameAs 3136244088 @default.
• W3136244088 citedByCount "8" @default.
• W3136244088 countsByYear W31362440882021 @default.
• W3136244088 countsByYear W31362440882022 @default.
• W3136244088 countsByYear W31362440882023 @default.
• W3136244088 crossrefType "journal-article" @default.
• W3136244088 hasAuthorship W3136244088A5006422020 @default.
• W3136244088 hasAuthorship W3136244088A5014341292 @default.
• W3136244088 hasAuthorship W3136244088A5018021256 @default.
• W3136244088 hasAuthorship W3136244088A5025216680 @default.
• W3136244088 hasAuthorship W3136244088A5033704922 @default.
• W3136244088 hasAuthorship W3136244088A5048339590 @default.
• W3136244088 hasAuthorship W3136244088A5081538316 @default.
• W3136244088 hasAuthorship W3136244088A5085965802 @default.
• W3136244088 hasBestOaLocation W31362440881 @default.
• W3136244088 hasConcept C117643217 @default.
• W3136244088 hasConcept C121608353 @default.
• W3136244088 hasConcept C126322002 @default.
• W3136244088 hasConcept C143998085 @default.
• W3136244088 hasConcept C2776232967 @default.
• W3136244088 hasConcept C2776256026 @default.
• W3136244088 hasConcept C2776694085 @default.
• W3136244088 hasConcept C2777982462 @default.
• W3136244088 hasConcept C2778347629 @default.
• W3136244088 hasConcept C2779013556 @default.
• W3136244088 hasConcept C2779422266 @default.
• W3136244088 hasConcept C2780258809 @default.
• W3136244088 hasConcept C2780379385 @default.
• W3136244088 hasConcept C2781182431 @default.
• W3136244088 hasConcept C2781230642 @default.
• W3136244088 hasConcept C71924100 @default.
• W3136244088 hasConceptScore W3136244088C117643217 @default.
• W3136244088 hasConceptScore W3136244088C121608353 @default.
• W3136244088 hasConceptScore W3136244088C126322002 @default.
• W3136244088 hasConceptScore W3136244088C143998085 @default.
• W3136244088 hasConceptScore W3136244088C2776232967 @default.
• W3136244088 hasConceptScore W3136244088C2776256026 @default.
• W3136244088 hasConceptScore W3136244088C2776694085 @default.
• W3136244088 hasConceptScore W3136244088C2777982462 @default.
• W3136244088 hasConceptScore W3136244088C2778347629 @default.
• W3136244088 hasConceptScore W3136244088C2779013556 @default.
• W3136244088 hasConceptScore W3136244088C2779422266 @default.
• W3136244088 hasConceptScore W3136244088C2780258809 @default.
• W3136244088 hasConceptScore W3136244088C2780379385 @default.
• W3136244088 hasConceptScore W3136244088C2781182431 @default.
• W3136244088 hasConceptScore W3136244088C2781230642 @default.
• W3136244088 hasConceptScore W3136244088C71924100 @default.
• W3136244088 hasLocation W31362440881 @default.
• W3136244088 hasLocation W31362440882 @default.
• W3136244088 hasOpenAccess W3136244088 @default.
• W3136244088 hasPrimaryLocation W31362440881 @default.
• W3136244088 hasRelatedWork W2022667262 @default.
• W3136244088 hasRelatedWork W2400744927 @default.
• W3136244088 hasRelatedWork W2516942920 @default.
• W3136244088 hasRelatedWork W2624310346 @default.
• W3136244088 hasRelatedWork W2742779675 @default.

• next